Want to see IN:ERIS full AI Analyst Report?
Top Page
Eris Lifesciences Ltd
(ERIS)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹1,226.00
▼(-12.36% Downside)
Action:Reiterated
Date:08/24/26
The score is primarily held back by weak cash-flow conversion and clear technical downtrend/momentum weakness (price below key moving averages with negative MACD). Strong operating profitability and improving leverage provide support, while valuation is only neutral given the 28.25 P/E and modest ~0.54% dividend yield.
Positive Factors
Strong Profitability
Healthy gross, operating, and net margins indicate strong earnings power in the branded-formulations model. This profitability can support continued brand promotion, product launches, and investment in the domestic sales force while providing resilience over the next several quarters.
Negative Factors
Weak Cash Conversion
Very low free-cash-flow conversion means reported earnings are not translating efficiently into cash, limiting internally funded investment and shareholder returns. The sharp year-over-year deterioration also makes liquidity planning and capital allocation less dependable over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
Healthy gross, operating, and net margins indicate strong earnings power in the branded-formulations model. This profitability can support continued brand promotion, product launches, and investment in the domestic sales force while providing resilience over the next several quarters.
Read all positive factors
Eris Lifesciences Ltd (ERIS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹165.08B
Dividend Yield0.61%
Average Volume (3M)9.02K
Price to Earnings (P/E)25.3
Beta (1Y)0.70
Revenue Growth9.59%
EPS Growth65.40%
CountryIN
Employees2,758
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)45.40
Shares Outstanding138,738,570
10 Day Avg. Volume6,235
30 Day Avg. Volume9,023
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)4.54
Price to Sales (P/S)5.67
P/FCF Ratio354.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)46.43
Revenue Forecast (FY)₹35.39B
Eris Lifesciences Ltd Business Overview & Revenue Model
Company Description
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of medicinal products throughout the country. The company provides a comprehensive range of branded formulations, catering to a...
How the Company Makes Money
Eris Lifesciences primarily makes money by selling branded pharmaceutical formulations in India. Its main revenue stream is domestic prescription-led sales of its portfolio of branded medicines to the pharmaceutical trade (e.g., distributors/stock...
Eris Lifesciences Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
71
Positive
Cash Flow
45
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.29B | 28.79B | 19.91B | 16.62B | 13.26B |
| Gross Profit | 14.98B | 21.49B | 16.04B | 13.05B | 10.65B |
| EBITDA | 11.11B | 10.36B | 6.99B | 5.48B | 5.11B |
| Net Income | 6.20B | 3.52B | 3.92B | 3.82B | 4.06B |
Balance Sheet | |||||
| Total Assets | 73.66B | 70.33B | 70.49B | 36.67B | 22.72B |
| Cash, Cash Equivalents and Short-Term Investments | 673.00M | 2.28B | 13.39B | 892.43M | 2.12B |
| Total Debt | 23.59B | 24.78B | 27.81B | 8.77B | 844.07M |
| Total Liabilities | 34.70B | 37.61B | 38.27B | 14.47B | 3.64B |
| Stockholders Equity | 39.03B | 28.54B | 25.86B | 21.96B | 19.08B |
Cash Flow | |||||
| Free Cash Flow | 500.70M | 9.10B | 3.57B | -5.50B | 2.57B |
| Operating Cash Flow | 3.47B | 10.65B | 4.86B | 2.92B | 3.78B |
| Investing Cash Flow | -3.72B | -799.70M | -18.55B | -9.82B | -3.20B |
| Financing Cash Flow | -1.20B | -8.81B | 13.80B | 6.88B | -446.99M |
Eris Lifesciences Ltd Technical Analysis
Negative
1398.90
Price Trends
1329.30
Negative
1367.53
Negative
1385.47
Negative
Market Momentum
-34.92
Positive
22.46
Positive
13.91
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ERIS, the sentiment is Negative. The current price of 1398.9 is above the 20-day moving average (MA) of 1289.14, above the 50-day MA of 1329.30, and above the 200-day MA of 1385.47, indicating a bearish trend. The MACD of -34.92 indicates Positive momentum. The RSI at 22.46 is Positive, neither overbought nor oversold. The STOCH value of 13.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ERIS.
Eris Lifesciences Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹160.20B | 23.22 | ― | 1.47% | 14.12% | 14.98% | |
66 Neutral | ₹626.52B | 28.96 | ― | 1.01% | 13.36% | -5.66% | |
66 Neutral | ₹659.36B | 36.59 | ― | 0.21% | 32.94% | 138.54% | |
63 Neutral | ₹1.81T | 73.98 | ― | 0.31% | 32.85% | 8.94% | |
59 Neutral | ₹1.04T | 51.22 | ― | 0.04% | 13.75% | 6.23% | |
56 Neutral | ₹165.08B | 25.33 | ― | 0.61% | 9.59% | 65.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:ERIS
Eris Lifesciences Ltd
1,189.85
-408.92
-25.58%
IN:ALKEM
Alkem Laboratories Ltd.
5,240.00
-195.77
-3.60%
IN:APLLTD
Alembic Pharmaceuticals Limited
815.00
-78.95
-8.83%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,336.30
367.06
18.64%
IN:MANKIND
Mankind Pharma Ltd.
2,527.00
75.10
3.06%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,761.95
1,267.65
36.28%
Eris Lifesciences Ltd Corporate Events
Eris Lifesciences Files Scrutinizer’s Report and Voting Results for 20th AGM
Sep 25, 2026
Eris Lifesciences Ltd has submitted to the BSE and NSE the consolidated scrutinizer’s report and voting results for its 20th Annual General Meeting held on September 25, 2026. The AGM was conducted via video conferencing, with shareholders e...
Eris Lifesciences Adds Veteran Investor Akhil Awasthi as Independent Director
Sep 21, 2026
Eris Lifesciences Ltd has appointed veteran investment professional Akhil Awasthi as an Additional Non-Executive Independent Director for a five-year term starting September 26, 2026, following approval by the board based on the nomination committ...
Eris Lifesciences Schedules Investor Meet With Bank of India Mutual Fund
Sep 7, 2026
Eris Lifesciences Limited has scheduled an in-person meeting with Bank of India Mutual Fund on September 10, 2026, as part of its ongoing engagement with institutional investors. The interaction, to be attended by management representative Krishna...
Eris Lifesciences to Hold 20th AGM Virtually, Expands E-Voting Access
Sep 2, 2026
Eris Lifesciences Ltd, an Indian branded formulations pharmaceutical player focused on chronic and lifestyle therapies, maintains a domestic market presence through listings on BSE and NSE and adheres to Indian corporate governance requirements. T...
Eris Lifesciences Secures ₹64.4 Crore Working Capital Loan Without Raising Debt Burden
Aug 6, 2026
Eris Lifesciences Ltd has drawn down a working capital term loan of ₹64.4 crore from Axis Bank Ltd to meet short-term liabilities, while clarifying that its overall debt level will remain unchanged. The facility, sanctioned on August 5, 2026...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.